Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Drug Synergism
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ pharmacology
Immune Checkpoint Inhibitors
/ pharmacology
Kaplan-Meier Estimate
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Progression-Free Survival
Response Evaluation Criteria in Solid Tumors
NSCLC
immunotherapy
lung cancer
statins
survival
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
23
02
2021
received:
05
01
2021
accepted:
01
03
2021
pubmed:
1
4
2021
medline:
5
2
2022
entrez:
31
3
2021
Statut:
ppublish
Résumé
Recent researches suggested that statins, beside their role in inhibiting endogenous cholesterol synthesis and in cardiovascular prevention, could influence several processes in cancer biology. In fact, a recent meta-analysis demonstrated that statins could positively influence OS in lung cancer patients. There is a lack of large cohort studies that could support a potential antineoplastic role of statins in clinical practice. We collected data from 162 patients treated with immunotherapy for Nonsmall Cell Lung Cancer (NSCLC) in first- and second-line setting to investigate the impact of these drugs on survival parameters. In our observational study, we enrolled 162 patients who received immunotherapy for lung cancer between October 2015 and April 2020. We used descriptive statistics to analyze patients' baseline features. Tumor response was evaluated using RECIST version 1.1 guidelines. Uni and multivariate analysis were conducted to investigate the relationship between statin use and response to immunotherapy, using the χ Although in our study, statin use positively correlates with PFS and OS in lung cancer patient treated with immunotherapy, these results require a further validation with randomized clinical trials.
Sections du résumé
BACKGROUND
Recent researches suggested that statins, beside their role in inhibiting endogenous cholesterol synthesis and in cardiovascular prevention, could influence several processes in cancer biology. In fact, a recent meta-analysis demonstrated that statins could positively influence OS in lung cancer patients.
AIM
There is a lack of large cohort studies that could support a potential antineoplastic role of statins in clinical practice. We collected data from 162 patients treated with immunotherapy for Nonsmall Cell Lung Cancer (NSCLC) in first- and second-line setting to investigate the impact of these drugs on survival parameters.
METHODS AND RESULTS
In our observational study, we enrolled 162 patients who received immunotherapy for lung cancer between October 2015 and April 2020. We used descriptive statistics to analyze patients' baseline features. Tumor response was evaluated using RECIST version 1.1 guidelines. Uni and multivariate analysis were conducted to investigate the relationship between statin use and response to immunotherapy, using the χ
CONCLUSION
Although in our study, statin use positively correlates with PFS and OS in lung cancer patient treated with immunotherapy, these results require a further validation with randomized clinical trials.
Identifiants
pubmed: 33788420
doi: 10.1002/cnr2.1368
pmc: PMC8388159
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1368Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Crit Rev Oncol Hematol. 2018 May;125:41-47
pubmed: 29650275
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618794133
pubmed: 30215300
Oncologist. 2015 Aug;20(8):934-45
pubmed: 26156329
Lung Cancer. 2016 Sep;99:137-42
pubmed: 27565929
Cancer Rep (Hoboken). 2021 Aug;4(4):e1368
pubmed: 33788420
Gen Physiol Biophys. 2017 Dec;36(5):501-511
pubmed: 29372683
Cell. 2018 Nov 1;175(4):1059-1073.e21
pubmed: 30270039
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Ann Oncol. 2019 Mar 1;30(3):385-396
pubmed: 30657859
Drug Des Devel Ther. 2019 Jan 23;13:405-422
pubmed: 30774306
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Radiol Clin North Am. 2018 May;56(3):485-495
pubmed: 29622080
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Cell Physiol. 2012 Apr;227(4):1709-20
pubmed: 21688263
Cancer Treat Rev. 2019 May;75:39-51
pubmed: 30954906
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Transl Lung Cancer Res. 2019 Oct;8(5):692-699
pubmed: 31737505
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
Crit Rev Oncol Hematol. 2014 Dec;92(3):296-311
pubmed: 25220658
Transl Lung Cancer Res. 2018 Jun;7(3):220-233
pubmed: 30050761
PLoS One. 2018 Dec 20;13(12):e0209486
pubmed: 30571754
Mol Clin Oncol. 2019 Jan;10(1):137-143
pubmed: 30655989
Nat Rev Immunol. 2006 May;6(5):358-70
pubmed: 16639429
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977